Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.

Cristiana Bellan¹, Lazzi Stefano, De Falco Giulia

¹Department of Human Pathology and Oncology, University of Siena, Siena, Italy.

Hematological Oncology

|October 22, 2009

Summary

Distinguishing Burkitt Lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL) is crucial for treatment. This review details diagnostic methods for these aggressive B-cell lymphomas and unclassifiable variants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Editorial: EBV strategies to counteract the immune response.

Frontiers in immunology·2026

Same author

Virtual Evaluation of Hematoxylin & Eosin via Digital Pathology Survey (VEED) Project: Results from a Non-Inferiority Study of a Tabs-Based Staining Method.

Diagnostics (Basel, Switzerland)·2026

Same author

Correction: P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma.

Cell death & disease·2026

Same author

An oncogenic role for EBV-encoded BILF1 in nasopharyngeal carcinoma.

The Journal of pathology·2026

Same author

Hit-and-run hypothesis: revisiting the impact of EBV in malignancies.

Frontiers in immunology·2026

Same author

Immune disparities in the TME of EBV+ and EBV- BL: role of reactive oxygen species generation pathways and platelet activation.

Blood advances·2026

Area of Science:

Hematology
Oncology
Pathology

Background:

Burkitt Lymphoma (BL) is an aggressive B-cell non-Hodgkin's lymphoma characterized by rapid proliferation and c-MYC gene deregulation.
Distinguishing BL from diffuse large B-cell lymphoma (DLBCL) presents diagnostic challenges, particularly in adults with intermediate features.

Purpose of the Study:

To review current diagnostic approaches for differentiating BL from DLBCL.
To address the classification of B-cell lymphomas with intermediate features between BL and DLBCL.

Main Methods:

Utilizing a comprehensive panel of antibodies for immunophenotypic analysis.
Employing cytogenetic and molecular diagnostic techniques.
Reviewing morphological assessment criteria.

Related Experiment Videos

Last Updated: Jun 19, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Main Results:

The study highlights the complexity in classifying certain B-cell lymphomas.
Diagnostic tools are essential for accurate differentiation between BL and DLBCL.
The WHO classification now includes an intermediate category for unclassifiable B-cell lymphomas.

Conclusions:

Accurate differentiation between BL and DLBCL is critical for appropriate patient management.
A multi-faceted diagnostic approach combining morphology, immunophenotyping, and molecular/cytogenetic analysis is necessary.
The updated WHO classification acknowledges the spectrum of B-cell lymphomas.